{"classes":[{"categories":[{"measurements":[{"comment":"NA: not estimable due to number of censored participants at the time the analysis cut off date was reached.","groupId":"OG000","lowerLimit":"2.8","upperLimit":"NA","value":"NA"},{"comment":"NA: not estimable due to number of censored participants at the time the analysis cut off date was reached.","groupId":"OG001","lowerLimit":"1.9","upperLimit":"NA","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"The Duration of Response (DoR) was defined as the time from initially meeting the criteria for response (CR or PR) until the time of progression by RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"* 30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.\n* Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).\n* Concomitant amino acids were given with each administration for kidney protection.\n* 177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.\n* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed.","id":"OG000","title":"177Lu-DOTA0-Tyr3-Octreotate"},{"description":"* 60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.\n* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed.","id":"OG001","title":"Octreotide LAR"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS). Only Participants with an Objective Response are included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached on 24July2015, assessed up to approximately 34 months","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}